SCHEMBL4358722

SCHEMBL4358722

O=C1N=C(N2CCOCC2)SC1=Cc1ccc(OCc2ccccc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.68
ALDH1A1 P00352 3/20 0.68
KDM4E B2RXH2 1/20 0.68
GAA P10253 1/20 0.68
MEN1 O00255 6/20 0.59
KMT2A Q03164 6/20 0.59
GRIN1 Q05586 2/20 0.58
GRIN2B Q13224 2/20 0.58
DCTPP1 Q9H773 1/20 0.58
HPGD P15428 2/20 0.57
ALOX5 P09917 2/20 0.57
CYP1A2 P05177 2/20 0.55
CYP2C19 P33261 2/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
PTPN1 P18031 1/20 0.55
POLB P06746 1/20 0.55
MAOA P21397 1/20 0.55
MAOB P27338 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4358719 1.00 MAPT (0.68) MAPTALDH1A1KDM4EGAAMEN1
SCHEMBL4359782 0.89 ALDH1A1 (0.57) MAPTALDH1A1KDM4EGAAMEN1
SCHEMBL4359781 0.89 ALDH1A1 (0.57) MAPTALDH1A1KDM4EGAAMEN1
SCHEMBL4350333 0.87 MAPT (0.57) MAPTALDH1A1KDM4EGAAMEN1
SCHEMBL4350336 0.87 MAPT (0.57) MAPTALDH1A1KDM4EGAAMEN1
SCHEMBL4352017 0.86 ALDH1A1 (0.74) MAPTALDH1A1KDM4EGAAMEN1
SCHEMBL4352015 0.86 ALDH1A1 (0.74) MAPTALDH1A1KDM4EGAAMEN1
SCHEMBL4354258 0.84 ALDH1A1 (0.78) MAPTALDH1A1KDM4EGAAMEN1
SCHEMBL4354253 0.84 ALDH1A1 (0.78) MAPTALDH1A1KDM4EGAAMEN1
SCHEMBL4350796 0.84 MEN1 (0.62) MAPTALDH1A1KDM4EGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 MAPT 1470/4885ALDH1A1 284/4885KDM4E 3224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.